Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients
- Conditions
- Colostomy Stoma
- Interventions
- Device: Hydrustoma C3Device: Coloplast Alterna
- Registration Number
- NCT05466721
- Lead Sponsor
- Hydrumedical
- Brief Summary
The surgical ostomy process happens when it is necessary to open an organ (such as the intestine) in order to maintain a communication channel with the external environment. The need for ostomy surgery can happen as a result of illness, genetic factors, or trauma. Despite the extensive improvements in colorectal surgery, in case there is a need for total or partial extraction and exteriorization of the large intestine (colostomy), it is often necessary to perform a stoma that connects the end of the preserved intestine to the skin, in which cases it is necessary to place a a colostomy bag for stool collection. Thus, there is a substantial number of patients who need to live with a permanent abdominal stoma that significantly affects their quality of life, implying significant changes, both physical and social. It will then be necessary for patients to adjust their daily routines in order to deal with stoma care.
The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
- Written informed consent;
- Male and Female patients;
- Adult aged ≥ 18;
- Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study;
- Having formed stool and using a flat ostomy appliance;
- Able to understand the study procedures and fill questionaries;
- Able to apply and remove the ostomy device autonomously.
- Repeated experiences of leakage with the usual ostomy device,
- Chronically liquid stools,
- Peristomal skin disorders,
- Known allergic reactions to components of the device,
- Receiving chemotherapy, radiation therapy or steroids in the previous month
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Hydrustoma C3 Hydrustoma C3 The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days. Hydrustoma C3 Coloplast Alterna The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days. Coloplast Alterna Hydrustoma C3 The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days. Coloplast Alterna Coloplast Alterna The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
- Primary Outcome Measures
Name Time Method Adverse effects 14 days Safety evaluations will be done by monitoring adverse events.
Efficacy of the device (journal of capsule/bag changes) 14 days Efficacy will be accessed by asking patients to record on a journal/diary, for each capsule/bag change, what was the reason for the change, and the occurrence and level of leakage.
Quality of life of the participant (Stoma Quality of Life questionnaire) 14 days In order to compare stoma related quality of life in patients with colostomy when using a control device and the Hydrustoma C3 devices the Stoma Quality of Life questionnaire will be used. This questionnaire is composed of 20 questions. Example of question "I worry that the bag detaches.". All questions must be answered on a scale of 1 to 4, being 1 always and 4 never.
Safety of the device (Discolouration, Erosion, Tissue overgrowth score) 14 days Safety evaluations will be done by monitoring the peristomal skin using the validated Ostomy Skin tool (DET score). The DET Score is calculated by examining the peristomal skin and evaluate the skin based on the descriptions in each of the 3 domains, discolouration (D), erosion (E) and tissue overgrowth (T); and assessing the size of the area affected in each of the 3 domains. The total score is (maximum 15) calculated by adding all of the subscores from each domain together.
- Secondary Outcome Measures
Name Time Method Satisfaction of the participant (questionnaire) 14 days The patients will be asked to evaluate the medical device in terms of application, discretion of the device, stoma related noise, feelings of security (confidence) and overall satisfaction of use (including comfort and impact on body image). The questionnaire has 8 questions of multiple choice (example "Regarding the safety during usage of the devices, I feel: (1) very insecure; (2) moderately insecure; (3) Moderadately secure; (4) Very secure") and 1 open answer question.
Trial Locations
- Locations (6)
Hospital de Braga
🇵🇹Braga, Portugal
Centro Hospitalar de Vila Nova de Gaia/Espinho
🇵🇹Vila Nova De Gaia, Portugal
Centro Hospitalar de Trás-os-Montes e Alto Douro
🇵🇹Vila Real, Portugal
Hospital Da Senhora Da Oliveira - Guimarães
🇵🇹Guimarães, Braga, Portugal
Centro Hospitalar de Entre o Douro e Vouga
🇵🇹Santa Maria Da Feira, Portugal
Centro Hospitalar do Tâmega e Sousa
🇵🇹Penafiel, Portugal